Helixgate https://validator.w3.org/feed/docs/rss2.html Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal Home Roche pours $750M into Oregon manufacturing plant as obesity push expands Five-Year Brain Organoids Reveal New Insights Into Human Development STAT+: HHS document offers new clues to Kennedy’s vaccine plans Lawmakers urge FDA to enact new China policies after 3 gene therapy deaths Werewolf and Ambros to tie the knot in $150M rare disease deal STAT+: Up and down the ladder: The latest comings and goings STAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and more Novo Nordisk starts trialing lower maintenance doses of oral Wegovy How cost and perception could reshape the GLP-1 market Opinion: Lil Nas X’s bipolar diagnosis and the paradox of treatment Focal therapy for localized prostate cancer has divided physicians. Will new data change minds? AI Identifies Pre-existing Antimicrobial Antibody Profile That May Predict Immune Response to Vaccination Scientists Analyze 267 Receptors That Control Protein Fate in Rare Diseases Regeneron to challenge Ipsen as FDA clears bone disease drug Cancer vaccine win restores Wall Street’s faith in Moderna Scribe’s early-stage IPO standout defies biotech’s derisking trend STAT+: How a Trump loyalist got the FDA nomination STAT+: FDA approves Ultragenyx gene therapy DDII Digital Forum: Resilience, smarter labs, therapeutics, and capital flows STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more From Models to Agents: The Next Phase of AI Adoption in Molecular Discovery Regeneron wins FDA approval to challenge Ipsen for rare bone disease market Built Without Bacteria: Bringing Cell-Free Synthesis to the Bench Lab-Grown Neocortex Models Mimic Early Brain Organization Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection Chai tees up Bristol Myers Squibb AI antibody discovery collab Reduce protein to increase longevity? Nutrition experts say that’s a bad idea Out of sight, out of work? What’s driving remote job cuts 7 biopharma M&A deals where layoffs followed Why pediatric rare oncology outperforms in a volatile biotech market Intracellular protein binders for imaging, control and future therapeutics Human Multi-Organ Chip Offers New Insight Into Cancer Metastasis STAT+: How Trump loyalist Heidi Overton became the president’s pick to run the FDA Abundance of Rare Immune Cell Type in Supercentenarians May Help Maintain Healthy Aging STAT+: New CDC director tells staff she is prepared to speak ‘truth to power’ Trump’s FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: analysts Trust in science: A new STAT initiative CAR T Manufacturing Innovation Expands Patient Access Trump nominates policy aide Overton to lead FDA Analysis: What Anthropic’s protein study says about its life-sciences aims STAT+: American Cancer Society cancels alcohol industry fundraiser MindMaze Therapeutics appoints strategic advisor for US growth Gene Switch Uses Electromagnetic Fields to Control Genes Remotely Rewriting the rules of CMV prevention 11 companies hiring in New Jersey Capricor investor calls for change as company awaits decision on Duchenne candidate Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future